Should BeyondSpring be a part of your Portfolio?
BeyondSpring, Inc. (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company focused on creating transformative treatments for immune-oncology conditions. The Company’s lead candidate is plinabulin, a selective immunomodulating microtubule-binding agent (SIMBA), which possess a unique mechanism of action and was evaluated in Phase 3 clinical trials in...
